Bioanalytical method development and validation of corynantheidine, a kratom alkaloid, using UPLC-MS/MS, and its application to preclinical pharmacokinetic studies

Journal of Pharmaceutical and Biomedical Analysis
2020.0

Abstract

Corynantheidine, a minor alkaloid found in Mitragyna speciosa (Korth.) Havil, has been shown to bind to opioid receptors and act as a functional opioid antagonist, but its unique contribution to the overall properties of kratom remains relatively unexplored. The first validated bioanalytical method for the quantification of corynantheidine in rat plasma is described. The method was linear in the dynamic range from 1-500鈥痭g/mL, requires a small plasma sample volume (25鈥痬uL), and a simple protein precipitation method for extraction of the analyte. The separation was achieved with Waters BEH C18 2.1鈥痻鈥?0鈥痬m column and the 3-minute gradient of 10鈥痬M ammonium acetate buffer (pH鈥?鈥?.5) and acetonitrile as mobile phase. The method was validated in terms of accuracy, precision, selectivity, sensitivity, recovery, stability, and dilution integrity. It was applied to the analysis of the male Sprague Dawley rat plasma samples obtained during pharmacokinetic studies of corynantheidine administered both intravenously (I.V.) and orally (P.O.) (2.5鈥痬g/kg and 20鈥痬g/kg, respectively). The non-compartmental analysis performed in Certara Phoenix(R) yielded the following parameters: clearance 884.1鈥?/-鈥?2.3鈥痬L/h, apparent volume of distribution 8.0鈥?/-鈥?.2鈥疞, exposure up to the last measured time point 640.3鈥?/-鈥?4.0鈥痟*ng/mL, and a mean residence time of 3.0鈥?/-鈥?.2鈥痟 with I.V. dose. The maximum observed concentration after a P.O. dose of 213.4鈥?/-鈥?0.4鈥痭g/mL was detected at 4.1鈥?/-鈥?.3鈥痟 with a mean residence time of 8.8鈥?/-鈥?.8鈥痟. Absolute oral bioavailability was 49.9鈥?/-鈥?6.4 %. Corynantheidine demonstrated adequate oral bioavailability, prolonged absorption and exposure, and an extensive extravascular distribution. In addition, imaging mass spectrometry analysis of the brain tissue was performed to evaluate the distribution of the compound in the brain. Corynantheidine was detected in the corpus callosum and some regions of the hippocampus. CI - Copyright (c) 2019 Elsevier B.V. All rights reserved.

Knowledge Graph

Similar Paper

Bioanalytical method development and validation of corynantheidine, a kratom alkaloid, using UPLC-MS/MS, and its application to preclinical pharmacokinetic studies
Journal of Pharmaceutical and Biomedical Analysis 2020.0
Preclinical pharmacokinetic study of speciociliatine, a kratom alkaloid, in rats using an UPLC-MS/MS method
Journal of Pharmaceutical and Biomedical Analysis 2021.0
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats
Journal of Natural Products 2021.0
Determination and pharmacokinetics of calycanthine in rat plasma by UPLC-MS/MS
Acta Chromatographica 2020.0
Pharmacokinetics, tissue distribution, and excretion studies of<scp>l</scp>-isocorypalmine using ultra high performance liquid chromatography with tandem mass spectrometry
Journal of Separation Science 2017.0
Analysis of Mitragynine and Speciociliatine in Umbilical Cord by LC–MS-MS for Detecting Prenatal Exposure to Kratom
Journal of Analytical Toxicology 2023.0
Establishment of LC-MS/MS method for determination of aloperine in rat plasma and its application in preclinical pharmacokinetics
Journal of Chromatography B 2021.0
Pharmacokinetic and bioavailability study of 5‐hydroxy‐4‐methoxycanthin‐6‐one, a typical canthinone alkaloid, in rats using ultra‐high performance liquid chromatography/electrospray ionization tandem mass spectrometry
Biomedical Chromatography 2020.0
A validated UHPLC-MS/MS method for measurement of pharmacokinetics and tissue distribution of trolline in rat
Journal of Pharmaceutical and Biomedical Analysis 2019.0
Clinical Pharmacokinetic Assessment of Kratom (Mitragyna speciosa), a Botanical Product with Opioid-like Effects, in Healthy Adult Participants
Pharmaceutics 2022.0